Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases

Abstract

Histone deacetylase inhibitors have generated keen interest as potential chemopreventive and chemotherapeutic agents due to their ability to induce cell cycle arrest, differentiation, and apoptosis in a diverse group of cancer derived cell lines. Activation of the 60 kDa non-receptor tyrosine kinase, c-Src, has been a consistent finding in many tumors and tumor derived cell lines, and has been implicated in these same cellular processes. We have shown that the histone deacetylase inhibitors, sodium butyrate and Trichostatin A, repressed c-Src mRNA and protein expression in a dose-dependent manner in cell lines derived from cancers of the colon, breast and liver. Our group has previously identified two distinct promoters that are responsible for SRC transcription, separated by a distance of approximately 1 kb. Sodium butyrate and Trichostatin A strongly inhibited activity of each of these highly disparate SRC promoters, demonstrating histone deacetylase inhibitors directly repress SRC transcription. This repression did not require protein neosynthesis and was not associated with a decrease in binding of protein factors essential for either promoter's activity. Our finding that sodium butyrate and Trichostatin A inhibit both SRC promoters suggest this oncogene may be a major target of these agents, and may explain in part their anti-cancer activity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Andrews NC, Faller DV . 1991 Nucleic Acids Res. 19: 2499

  • Archer SY, Meng S, Shei A, Hodin RA . 1998 Proc. Natl. Acad. Sci. USA 95: 6791–6796

  • Bannister AJ, Miska EA, Gorlich D, Kouzarides T . 2000 Curr. Biol. 10: 467–470

  • Biscardi JS, Belsches AP, Parsons SJ . 1998 Mol. Carcinog. 21: 261–272

  • Biscardi JS, Tice DA, Parsons SJ . 1999 Adv. Cancer Res. 76: 61–119

  • Bonham K, Fujita DJ . 1993 Oncogene 8: 1973–1981

  • Bonham K, Ritchie SA, Dehm SM, Snyder K, Boyd FM . 2000 J. Biol. Chem. 275: 37604–37611

  • Chiang CM, Roeder RG . 1995 Science 267: 531–536

  • Chomczynski P, Sacchi N . 1987 Anal. Biochem. 162: 156–159

  • Cuisset L, Tichonicky L, Jaffray P, Delpech M . 1997 J. Biol. Chem. 272: 24148–24153

  • D'Argenio G, Cosenza V, Della Cave M, Iovino P, Delle Valle N, Lombardi G, Mazzacca G . 1996 Gastroenterology 110: 1727–1734

  • Dehm S, Senger MA, Bonham K . 2001 FEBS Lett. 487: 367–371

  • Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, Brosch G, Wintersberger E, Seiser C . 1999 Mol. Cell. Biol. 19: 5504–5511

  • Espinos E, Le Van Thai A, Pomies C, Weber MJ . 1999 Mol. Cell. Biol. 19: 3474–3484

  • Foss FM, Veillette A, Sartor O, Rosen N, Bolen JB . 1989 Oncogene Res. 5: 13–23

  • Gamet L, Daviaud D, Denis-Pouxviel C, Remesy C, Murat JC . 1992 Int. J. Cancer 52: 286–289

  • Gu W, Roeder RG . 1997 Cell 90: 595–606

  • Hague A, Manning AM, Hanlon KA, Huschtscha LI, Hart D, Paraskeva C . 1993 Int. J. Cancer 55: 498–505

  • Han JW, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee YW, Lee HW . 2001 J. Biol. Chem. 276: 42084–42090

  • Hass R, Busche R, Luciano L, Reale E, Engelhardt WV . 1997 Gastroenterology 112: 875–881

  • Huang L, Sowa Y, Sakai T, Pardee AB . 2000 Oncogene 19: 5712–5719

  • Iacomino G, Tecce MF, Grimaldi C, Tosto M, Russo GL . 2001 Biochem. Biophys. Res. Commun. 285: 1280–1289

  • Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ . 1999 Nat. Genet. 21: 187–190

  • Irby RB, Yeatman TJ . 2000 Oncogene 19: 5636–5642

  • Karni R, Jove R, Levitzki A . 1999 Oncogene 18: 4654–4662

  • Kouzarides T . 2000 EMBO J. 19: 1176–1179

  • Lee JS, Galvin KM, Shi Y . 1993 Proc. Natl. Acad. Sci. USA 90: 6145–6149

  • Luciano L, Hass R, Busche R, von Engelhardt R, Reale E . 1996 Cell Tissue Res. 286: 81–92

  • Mandal M, Kumar R . 1996 Cell. Growth Differ. 7: 311–318

  • Mariadason JM, Corner GA, Augenlicht LH . 2000 Cancer Res. 60: 4561–4572

  • Marks PA, Richon VM, Breslow R, Rifkind RA . 2001a Curr. Opin. Oncol. 13: 477–483

  • Marks PA, Rifkind RA, Richon VM, Breslow R . 2001b Clin. Cancer Res. 7: 759–760

  • Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T . 2000 EMBO J. 19: 662–671

  • Maruta H, Greer K, Rosenbaum JL . 1986 J. Cell Biol. 103: 571–579

  • McIntyre A, Gibson PR, Young GP . 1993 Gut 34: 386–391

  • Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H, Sakai T . 1997 J. Biol. Chem. 272: 22199–22206

  • Rajala RV, Dehm S, Bi X, Bonham K, Sharma RK . 2000 Biochem. Biophys. Res. Commun. 273: 1116–1120

  • Reddy BS . 1995 Crit. Rev. Food Sci. Nutr. 35: 175–190

  • Richon VM, Sandhoff TW, Rifkind RA, Marks PA . 2000 Proc. Natl. Acad. Sci. USA 97: 10014–10019

  • Ritchie S, Boyd FM, Wong J, Bonham K . 2000 J. Biol. Chem. 275: 847–854

  • Schwartz B, Avivi-Green C, Polak-Charcon S . 1998 Mol. Cell. Biochem. 188: 21–30

  • Sealy L, Chalkley R . 1978 Cell 14: 115–121

  • Singh B, Halestrap AP, Paraskeva C . 1997 Carcinogenesis 18: 1265–1270

  • Souleimani A, Asselin C . 1993 FEBS Lett. 326: 45–50

  • Soutoglou E, Papafotiou G, Katrakili N, Talianidis I . 2000 J. Biol. Chem. 275: 12515–12520

  • Sowa Y, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H, Sakai T . 1999 Cancer Res. 59: 4266–4270

  • Staley CA, Parikh NU, Gallick GE . 1997 Cell Growth Differ. 8: 269–274

  • Suzuki T, Yokozaki H, Kuniyasu H, Hayashi K, Naka K, Ono S, Ishikawa T, Tahara E, Yasui W . 2000 Int. J. Cancer 88: 992–997

  • Topping DL, Clifton PM . 2001 Physiol. Rev. 81: 1031–1064

  • Toscani A, Soprano DR, Soprano KJ . 1988 Oncogene Res. 3: 223–238

  • Trock B, Lanza E, Greenwald P . 1990 J. Natl. Cancer Inst. 82: 650–661

  • Van Lint C, Emiliani S, Verdin E . 1996 Gene Expression 5: 245–253

  • Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema J, Hennipman A, Rijksen G . 1996 J. Pathol. 180: 383–388

  • Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC . 2001 Clin. Cancer Res. 7: 971–976

  • Yoshida M, Kijima M, Akita M, Beppu T . 1990 J. Biol. Chem. 265: 17174–17179

Download references

Acknowledgements

This study was supported by operating grants to K Bonham from the Canadian Institute of Health Research (CIHR) and the Saskatchewan Cancer Agency. S Dehm was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) Scholarship.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Keith Bonham.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kostyniuk, C., Dehm, S., Batten, D. et al. The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases. Oncogene 21, 6340–6347 (2002). https://doi.org/10.1038/sj.onc.1205787

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205787

Keywords

This article is cited by

Search

Quick links